Virtual reality could be used to design new drugs, say researchers
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
List view / Grid view
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
A study has shown that using a particular three-stranded structure can extend the catalytic performance of artificial metalloenzymes.
Researchers have found that there is less calmodulin binding to ion channels in the T cells from cancer patients, presenting a new immunotherapeutic target.
A new study has revealed five factors and proteins that hepatitis B infection needs for replication of its DNA, providing insight into the disease.
Using fluorescent markers, researchers have developed Förster resonance energy transfer (FRET) to image the assembly, functions and interactions of molecules.
Researchers have successfully treated cardiac dysfuntion in mice models of Barth syndrome by using a gene therapy to replace TAZ.
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
A collaborative team has developed a compound called WM382, which targets two crucial enzymes in the malaria parasite, effectively killing it.
International researchers have analysed nearly 1,900 brain samples to create the Brain Atlas, the latest database released by the Human Protein Atlas (HPA) project.
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
Researchers have used cryogenic electron microscopy to show that coronaviruses enter human cells through an interaction with angiotensin-converting enzyme 2 (ACE2).
A new study conducted in Israel suggests that T cells’ ability to destroy skin cancer increases in the absence of T-cell regulators called SLAMF6.
Scientists suggest competence-blocking, ‘anti-evolution’ drugs could be administered alongside antibiotics to prolong the period before bacterial resistance emerges.
Researchers have developed a compound, called AB569, effective at combatting bacteria such as Pseudomonas aeruginosa and have revealed its mechanism of action.